vaishali pharma has initiated a postal ballot process to seek shareholder approval for the re-appointment of three directors and a revision in remuneration for its Director cum Chief Financial Officer. The resolutions, which require special approval, pertain to the re-appointment of Mr. Pratik Vikram Jakhelia as an Independent Director, Mr. Atul Arvind Vasani as Managing Director, and Mrs. Jagruti Vasani as a Whole-Time Director, alongside a remuneration increase for Mr. Dewansh Ajay Vasani.

The Board of Directors, at its meeting held on May 23, 2026, approved the proposals based on the recommendations of the Nomination and Remuneration Committee. The re-appointments are for a term of five years, commencing from May 23, 2026, for the executive directors and from October 1, 2026, for the Independent Director. The remuneration revisions for Mr. Atul Arvind Vasani and Mrs. Jagruti Vasani exceed the limits prescribed under Schedule V of the Companies Act, 2013, necessitating shareholder consent via special resolution.

The company has engaged Central Depository Services (India) Limited (CDSL) to facilitate the remote e-voting process. The voting period begins at 10:00 A.M. IST on Thursday, June 4, 2026, and ends at 5:00 P.M. IST on Friday, July 3, 2026. Shareholders whose names appear in the Register of Members or Register of Beneficial Owners as on the cut-off date of May 22, 2026, are eligible to vote.

Remuneration Details

The postal ballot notice outlines specific remuneration structures for the directors seeking re-appointment and the proposed revision for the CFO. The remuneration for Mr. Atul Arvind Vasani is proposed to increase from ₹84 Lakhs per annum to ₹96 Lakhs per annum, while Mrs. Jagruti Vasani’s remuneration is set to rise from ₹24 Lakhs per annum to ₹30 Lakhs per annum.

The re-appointment of Mr. Pratik Vikram Jakhelia as an Independent Director is for a second term of five years, ending on September 30, 2031. He is not liable to retire by rotation and will be entitled to sitting fees and remuneration for attending Board and Committee meetings as approved by the Board.

Voting and Results

HD and Associates, Practicing Company Secretary, has been appointed as the Scrutinizer to ensure the conduct of the postal ballot is fair and transparent. The results of the postal ballot will be announced on or before 5:00 P.M. IST on Tuesday, July 7, 2026, and will be submitted to the stock exchanges within two working days of the conclusion of the e-voting period.

In compliance with Ministry of Corporate Affairs circulars, the notice is being sent only through electronic mode to members whose email addresses are registered with the company or depositories. The company has stated that hard copies of the postal ballot notice and forms will not be dispatched to members.

Vaishali Pharma Limited reported a net profit of ₹403.17 lakh for the financial year ended March 31, 2026, a significant increase from ₹81.74 lakh in the previous year. Revenue from operations rose to ₹10,877.23 lakh for FY26, compared to ₹9,902.56 lakh in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, in a meeting held on May 30, 2026.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹26.64 lakh, while revenue from operations stood at ₹2,692.71 lakh. Total income for the quarter was ₹2,818.91 lakh. The earnings per share (EPS) for the year ended March 31, 2026, was reported at ₹0.31 on a basic and diluted basis, up from ₹0.06 in the previous year.

Standalone Financial Performance

The standalone financial statements for the year ended March 31, 2026, reflect a growth in profitability. Total expenses for the year were ₹10,722.07 lakh, up from ₹10,100.52 lakh in the prior year. Finance costs increased to ₹196.25 lakh from ₹158.30 lakh in FY25. The profit before tax for the year stood at ₹538.69 lakh, compared to ₹122.58 lakh in the previous year.

Auditor’s Observations

The statutory auditors, Raman S. Shah & Associates, issued an audit report with an unmodified opinion on the financial results. However, the auditors highlighted a matter regarding current assets. The company has trade receivables of ₹5,077.26 lakh, deposits, loans, and advances of ₹3,199.85 lakh, and other current assets of ₹2,344.86 lakh. These balances include a substantial value of receivables outstanding for more than three years. The auditors stated they are unable to comment on adjustments that may be required to the carrying value of these assets and the consequential impact on the financial statements. Trade receivables amounting to ₹226.90 lakh were written off during the year.

Consolidated Results and Associate

The consolidated financial results include the accounts of associate Kesar Pharma Limited, which the company acquired in September 2025. The share of profit from the associate for the year ended March 31, 2026, was ₹13.31 lakh. The consolidated net profit for the year was ₹416.48 lakh. The company noted that comparative consolidated figures for the previous year are not presented as consolidation was not applicable prior to the acquisition.